GlaxoSmithKline (GSK) announced on Monday that the combination of its cancer drugs Zejula and Jemperli, utilized as a maintenance therapy following Jemperli plus chemotherapy, has successfully met the main goal in a late-stage trial targeting a specific type of endometrial cancer.
The trial results indicated that the sequential treatment of Jemperli plus chemotherapy followed by Jemperli and Zejula led to an improvement in progression-free survival. This improvement was observed in both the overall patient population and a subpopulation of patients with specific types of tumors. Progression-free survival measures the duration a patient lives without the disease worsening after receiving treatment.
GSK described the trial’s outcome as having achieved a “statistically significant and clinically meaningful” benefit for the concerned patients. The ongoing analysis of the full trial data will include the key secondary endpoint of overall survival.
GSK has been actively working to rebuild its oncology business, and the approval of Jemperli in the United States and the UK for treating certain subtypes of advanced or recurrent endometrial cancer in combination with chemotherapy has been a significant boost.
Zejula, GSK’s leading cancer drug in terms of revenue in 2022, accounted for approximately 77% of the company’s £602 million ($763.8 million) sales from its oncology business. The continued success and expansion of the Zejula and Jemperli combination therapy hold the potential to further strengthen GSK’s position in the oncology market.
The analysis of overall survival data will provide a more comprehensive understanding of the treatment’s efficacy. GSK remains committed to advancing its oncology portfolio and contributing to advancements in cancer care.
($1 = £0.7881)